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RESUMEN
La introducción de técnicas de diagnóstico no basadas en 
cultivo está revolucionando el mundo del diagnóstico micro-
biológico y de la aproximación a las infecciones. Los hongos 
no son una excepción, y la introducción de biomarcadores ha 
abierto enormes expectativas para una mejor manejo de estas 
enfermedades. Hay diversos biomarcadores cuyo significado 
es también diverso pero su evaluación se ha hecho prefer-
entemente en un uso individual y con estudios con distitnos 
diseños. Se sabe menos sobre el valor de la combinación de 
biomarcadores y el impacto de la negatividad de dos o más 
de los mismos en las decisiones de tratamiento antifúngico ha 
sido poco estudiado. Dada la escasez de datos prospectivos, en 
estudios aleatorizados y definitivos, hemos convocado a ex-
pertos de diferentes campos con un interés en las infecciones 
micóticas invasivas, para responder a algunas preguntas sobre 
el uso actual y relevante de los biomarcadores fúngicos. Este 
documento resume las respuestas del grupo de expertos a las 
preguntas que se les formularon sobre el tema.
Palabras clave: Infección fúngica invasora, Cuidados intensivos, Cuidados 
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INTRODUCTION
Invasive Fungal Infection (IFI) is becoming increasing-
ly important due to a series of circumstances, including the 
growth of a population with multiple risk factors and immu-
nosuppressed, in which the control of bacterial infections is 
more effective. Exposure to both endogenous and exogenous 
fungi is favored by hospitalization and procedures that injure 
cutaneous-mucous barriers. Finally, the availability of effective 
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Dr. Benito Almirante 
Background:
Rodríguez-Tudela et al attempted to estimate the inci-
dence of IFIs in Spain in a 2015 publication [1]. They estimated 
that approximately 9.52 episodes of invasive candidiasis (IC) 
occur per 100,000 inhabitants and that in the case of Invasive 
Aspergillosis (IA) the figure was 2.75 episodes/100,000 inhab-
itants. The number of cases of mucormycosis was significant-
ly lower and was estimated at 0.04 episodes per 100,000 in-
habitants per year. They also estimated the figures for certain 
groups of patients and they reported that 4% of all solid organ 
transplants and 1.6% of all patients with malignant hemato-
logical diseases had, at one time or another, an IFI.
Table 1 lists some studies particularly aimed at evaluating 
the incidence of candidemia in Spain. As can be seen in table 
1, the figures per 100,000 inhabitants per year range from 4.3 
to 8.1 episodes and the data estimated with the denominator 
of 1.000 hospital admissions vary between 0.53 and 1.09 epi-
sodes.
At the time of detection of the episode of candidemia, 
patients in Spain were mostly hospitalized (88%) and a third 
(35%) were admitted to Intensive Care Units (ICUs). The med-
ical and surgical areas represented 28% and 21%, respective-
ly, and the pediatric areas 3%. A miscellany from other places 
represented only 1% [2].
The three invasive entities caused by Candida were can-
didemia in the absence of organ candidiasis, candidemia as-
sociated with organ disease and candidiasis of organs with-
out accompanying candidemia. The difficulties of diagnosis 
by conventional methods [7, 8] arise because the sensitivity 
of blood cultures does not exceed 50% and, when available, 
is often delayed more than 48 hours. In the case of organ IC, 
there are only positive reliable cultures in approximately 50%. 
Invasive procedures are frequently required to obtain proper 
samples but are rarely possible.
Regarding the conventional diagnosis of IA [9, 10] the 
challenges are not minor. Signs and symptoms are often non-
specific, it is difficult to distinguish colonization from infec-
tion, blood cultures are practically always negative and it is 
also difficult or impossible to perform invasive techniques for 
obtaining proper samples. The use of non-culture-based bio-
markers is therefore indispensable.
antifungal agents determines the need for rapid and accurate 
diagnosis. 
Culture-based diagnostic media have a recognized and 
clear role in the diagnosis of invasive mycosis but their defi-
ciencies are also known, particularly in sensitivity and also in 
speed.
Therefore, it is essential to implement the diagnosis of 
invasive mycosis with non-culture-based techniques among 
which biomarkers are already an essential part. However, the 
position of biomarkers of IFIs in everyday clinical use is far 
from uniform in all hospitals, the performance of some tech-
niques is under discussion, their interpretation is not always 
simple and the existing bibliography is sometimes biased for 
many reasons.
This has led to the convening of a series of experts from 
the fields of Microbiology, Infectious Diseases and Intensive 
Care, confronting them with a series of questions that seemed 
relevant. The open-door meeting took place in Madrid on 23 
May 2019 on the occasion of the National Congress of the 
Spanish Society of Infectious Diseases and Clinical Microbi-
ology (SEIMC). This document tries to reflect the main issues 
discussed, the documentation provided on them and the con-
clusions that were agreed by the group.
The final document, after having been edited and revised, 
has been approved by all the participants and represents the 
opinion of all of them and not necessarily of the institutions to 
which they belong.
MATERIAL AND METHODS
The questions were chosen by the coordinators and ac-
cepted by all the speakers. The document, edited in a first 
draft has been sent to all co-authors for their corrections and 
amendments. The final document has been reviewed and ap-
proved by all authors.
Next, we will review the questions posed, the arguments 
provided and the conclusions reached in each of them.
QUESTION 1. Could the importance of invasive fungal 
infection (IFI) in Spain be quantified? What proportion of 
it is confirmed by culture?
Reference Period N cases x105 inhabitants x104 days of hospital stay x103 hospital admissions
Almirante B, 2005 [3] 2002-03 345 4.3 0.73 0.53
Rodríguez-Hernández MJ, 2011 [4] 2005-06 220 ND 0.8 0.58
Cisterna R, 2010 [5] 2008-09 984 ND ND 1.09
Pemán J, 2012 [6] 2009-10 1,357 ND ND 0.92
Puig-Asensio M. CANDIPOP Project, 2013 [2] 2010-11 773 8.1 1.36 0.89
Table 1  Studies on the incidence of candidemia in Spain
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that allows to quantify these antibodies and it is commer-
cialized for the diagnosis of IC. 
The CAGTA test, in individualized use, has been eval-
uated on numerous occasions with different results. In a 
recent meta-analysis, the authors found an overall sensi-
tivity of 66% with a specificity of 76% [15]. In addition, in 
some studies, it has been possible to relate a higher anti-
body titer with a better prognosis in patients admitted to 
the ICU, so that it could be used as a prognostic marker 
depending on its kinetics [16].
Due to its limited diagnostic value, it has been at-
tempted to be used in combination with other biomarkers 
such as 1,3-ßDG, or antibodies and/or mannan antigens. 
Recently it has also been combined with the T2Candida 
magnetic resonance system. According to the different 
studies, the main usefulness of the combination of these 
biomarkers lies in their high negative predictive value. This 
implies that when an antifungal treatment is empirically 
established, the negativity of two of these markers could 
be sufficient to safely withdraw the treatment [17-19]. 
Conclusion:
CAGTA is a Candida antimicelial antibody detec-
tion system, developed in Spain and commercialized 
in the form of indirect immunofluorescence. Its neg-
ativity, when it coincides with that of other biomark-
ers, may allow the suspension of antifungal treat-
ments initiated on an empirical basis.
QUESTION 4. What are the indications and limita-
tions of the use of Galactomannan (GLM) in a general 
hospital at the present time?
Dr. Julio García Rodríguez
Background:
After the study published by the group of Duarte et al. 
[20] in haematological patients with high risk of fungal infec-
tion, who received prophylaxis with posaconazole, and later 
corroborated in patients on prophylactic treatment with mi-
cafungin [21], it has been determined the poor role that the 
detection of GLM alone plays in these populations when used 
Conclusion:
Invasive infection caused by Candida is estimated in 
Spain at 9.52 episodes per 100,000 inhabitants/year and 
that caused by Aspergillus at 2.75 episodes. Confirmation 
with culture occurs in less than 50% of cases due to the 
frequent negativity of blood cultures and the difficulty 
of obtaining deep samples of ordinarily sterile tissues or 
fluids.
QUESTION 2. How should “biomarker of fungal infec-




A biomarker of fungal infection is a “Biological product 
from the structure of the fungus/yeast, capable of being de-
tected by “unconventional” techniques, allowing (sometimes) 
an early and/or anticipated diagnosis of an invasive fungal in-
fection” [11].
Most common ones are summarized in table 2 and are, 
in the case of Candida, mannan and anti-mannan, antibod-
ies against Candida germinal tubes (CAGTA), 1-3-β-D-glucan 
(1-3-ßDG), nucleic acids and the T2Candida nanodiagnostic 
panel. In the case of IA, the most commonly used are: galac-
tomannan (GLM) in serum, BAL or other samples, 1-3-βDG, 
nucleic acids (serum, blood or other samples) and Aspergillus 
lateral flow assay (A-LFD) technology [9, 11-13].
Conclusion:
A biomarker of Invasive Fungal Infection is a biolog-
ical product from the structure of the fungus/yeast that 
can be detected by non-culture-based techniques. At this 
time, the most commonly used in the case of Candida are 
mannan and anti-mannan, antibodies against Candida 
germinal tubes (CAGTA), the 1-3-β-D-glucan, the detec-
tion of nucleic acids, and the T2Candida nanodiagnostic 
panel. In the case of Invasive Aspergillosis, galactoman-
nan, 1-3- β-D-glucan, nucleic acids, and Aspergillus lat-
eral flow assay (A-LFD) technology are the more common. 
QUESTION 3. What is CAGTA and what does it con-
tribute to the diagnosis of invasive candidiasis?
Dr. Julio García Rodríguez
Background:
The anti-micelium antibody detection system for the 
diagnosis of invasive candidiasis (IC) (CAGTA) is a tech-
nique developed at the University of the Basque Country 
(Spain) and marketed in the form of indirect immunofluo-
rescence [14]. It was originally designed for the detection 
of antibodies against antigens expressed in the mycelial 
phase of Candida albicans when it is invading tissues. 
However, it was soon found to be useful for the diagnosis 
of infections by other Candida species. It is a technique 
Biomarkers of invasive candidiasis Biomarkers of invasive aspergillosis
Mannan-Anti-mannan Galactomannan (Blood, BAL)
CAGTA Aspergillus Lateral Flow Assay
1-3-ß-D- Glucan 1-3-ß-D- Glucan
Nucleic acids Nucleic acids
Nanodiagnostic T2Candida
Table 2  Biomarkers of invasive fungal infection 
of common use
CAGTA: Candida albicans germ tube antibody
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mended in non-symptomatic hematological patients who 
are receiving antifungal prophylaxis. 




The performance of classical diagnostic tests on patients 
who are to be, or are undergoing, antifungal treatment is 
usually limited to patients who fall within the definition of 
pre-emptive treatment [28]. However, the use of biomarkers 
can also be useful to identify therapeutic or prophylaxis fail-
ures and can help to confirm or rule out disease in patients on 
empirical or early treatment or help to decide the duration and 
prognosis of patients with confirmed diagnosis. 
The 1-3-βDG is a component of the fungal wall composed 
mainly of glucose polymers joined by 1-3 glucosidic bonds 
that form the skeleton of the fungal wall. As the fungus grows, 
part of this compound is released into the blood, where it can 
be measured. Beta-glucans are able to activate the blood co-
agulation cascade of Limulus polyphemus, the North American 
horseshoe crab [29], which forms the basis of the diagnostic 
test. It is produced by fungi such as Aspergillus sp, Candida sp, 
Pneumocystis sp. Coccidioides sp, and Histoplasma sp. but is 
not produced in Cryptococcus sp and Mucorales. 
The positivity of 1-3-ßDG can anticipate by an average of 10 
days diagnostic clinical manifestations of invasive fungal infec-
tions [30]. In a study conducted by Tissot et al. [31], in patients 
with intra-abdominal candidiasis without candidemia, 1-3-ßDG 
became positive an average of 5 days before confirmation of the 
diagnosis. In addition, severe sepsis and mortality in this study 
were higher in patients with higher levels and persisted high, 
rather than falling, in patients with poor progression.
Determination of 1-3-ßDG can produce both false positives 
and false negatives. Causes of false positivity include hemodialysis 
with cellulose membranes, exposure of tissues to cotton gauze and 
other materials that may contain glucans, administration of blood 
products through filters, and some antimicrobials such as amoxi-
cillin-clavulanic, piperacillin-tazobactam, co-trimoxazole, colistin, 
cefepime, ertapenem, and others that suggest contamination with 
fungal fragments during production [32]. In general, in these cas-
es, the positivity of the test disappears quickly after suspension of 
the antibiotic or dilution of the sample. There are also false positives 
described in patients with bacteremia, particularly gram-negative 
bacteremia, but some studies show that a substantial proportion 
of bacteremic and 1-3-ßDG-positive patients have simultaneously 
possible, probable or proven mycoses [33]. Therefore, false positives 
may occur in patients with bacteremia but this is rare, and the pres-
ence of an underlying fungal infection or causes of false positivity 
other than bacteremia should always be suspected. Although Can-
dida colonization does not cause false positives, patients with mu-
cositis may have higher levels of 1-3-ßDG [34]. 
The classical (Fungitell) determination technique (using kinetic 
ELISA) has important practical limitations in an assistance labora-
as a weekly screening for the initiation of early preemptive an-
tifungal therapy. Both groups of researchers have pointed out 
that in a setting where the prevalence of IA is reduced to less 
than 2%, the pre-test probability of GLM falls dramatically, as 
does the positive predictive value. Therefore, any positive in 
this situation will be more likely to be a false positive than a 
true value. These false results may lead these patients to other 
more or less annoying confirmatory diagnostic tests and, on 
many occasions, to the initiation of nonrequired antifungal 
treatments. In short, an increase in the risk of iatrogeny and 
expenditure.
Although these studies currently advise against the use of 
GLM as a diagnostic anticipation tool in hematological patients 
undergoing antifungal prophylaxis, the test is still very useful in 
those situations in which the patient already has a clear clinical 
suspicion of IA [22]. There are also other circumstances in which 
this test is very useful, which are summarized below:
Detection in bronchoalveolar lavage (BAL). The latest 
reviews and meta-analyses have confirmed that detection of 
GLM in BAL is more sensitive than in serum, both in hemato-
logical and non-hematological patients [23, 24].
Extrapulmonary IA. Other situations in which the deter-
mination of GLM may be useful is in extrapulmonary forms of 
IA such as the case of cerebrospinal fluid for cerebral locali-
zations [25] or peritoneal fluid for the diagnosis of peritonitis 
[26]. 
Other applications. Recently, GLM has also been consid-
ered useful in the follow-up of high-risk patients in hospitals 
with undergoing works [27], as a prognostic marker of chronic 
aspergillosis and as a diagnostic test for disseminated fusario-
sis [27]. 
Difficulties. However, the format currently marketed by 
a microtiter plate capture ELISA makes it very difficult to use 
the test with only one or a few samples. Initially, a latex ag-
glutination for the detection of GLM antigen existed in a com-
mercialized form, which was substituted by the capture ELISA 
due to the greater analytical sensitivity of the latter. The ELISA 
method is useful when studying a large number of patients at 
risk of IA in a systematic way. New formats are now needed 
to facilitate its use with a single sample. These new systems 
must be able to quantify the fungal load and be easy to car-
ry out. One model would be the new immunochromatography 
based on “Lateral Flow”, which is a very simple, but difficult 
to quantify, technique. The new 1-3-ßDG detection test using 
WAKO turbidimetry could also be a suitable format. Finally, the 
new monotest using chemiluminescence developed by Vircell, 
in the absence of a clinical evaluation and published studies, 
could respond to these new diagnostic needs. 
Conclusion:
Galactomannan is a useful diagnostic test for the in-
vestigation of Invasive Aspergillosis in patients with clin-
ically suggestive conditions. It can be performed not only 
in blood but also in CSF, bronchoalveolar lavage or peri-
toneal fluid. Its systematic and periodic use is not recom-
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tients [38] and includes 6 cohort studies totaling 1,771 adults of 
whom 414 had IFIs (215 tested or probable). They did not detect 
discrepancies between the various commercially available tests. 
When the existence of two consecutive positive tests is used as 
a positive value, the sensitivity and specificity were respectively 
50% and 99%. For an estimated prevalence of 10% of IFIs the 
PPV and NPV were respectively 83.5% and 95%.
In a meta-analysis based exclusively on prospective stud-
ies [39], a total of 1,068 patients from 11 studies were exam-
ined and the cumulative data obtained were the following, 
with 95% confidence intervals: Sensitivity 75%, Specificity 
87%, Positive likelihood ratio 5.85, Negative likelihood ratio 
0.30, diagnostic odds ratio 19.53, and area under the summary 
receiver operating characteristic curve, of 0.89. This suggests 
that this is a clinically useful test with a high ability to distin-
guish between patients with and without IFI that should be 
used together with other clinical and microbiological data.
The interpretation requires always to exclude the most 
frequent causes of false positive summarized in table 3 and 
false negatives summarized in table 4.
In the case of P. jirovecii pneumonia (PJP) [40] 14 
studies allowed to analyze the result of 1-3-ßDG in 357 
cases and 1,723 controls. Cumulative data showed 95% 
sensitivity and 86% specificity. The positive and negative 
likelihood ratios were 6.9 and 0.06, respectively. The ar-
ea under the HSROC curve was 0.965. The serum 1-3-ßDG 
determination showed excellent sensitivity and very good 
specificity in the diagnosis of PJP. 
Nucci et al [41] have recently provided interesting da-
ta on the use of 1-3-ßDG in the diagnosis and prognosis 
tory as it almost never allows “real time” determination due to the 
need of batching serums for joint processing. It is also a long (ap-
prox. 3 hours) and laborious technique to perform (not suitable for 
inexperts). Only 10 µl of sample (serum) are used, and the minimum 
pipetting error can generate important errors in the result (usually 
false negatives). In the new format of the technique (WAKO/FUJIF-
ILM), based on the detection of 1-3-ßDG by chemiluminescence in 
MONOTEST format, it allows to analyze sera individually, in much 
less time (45-90 minutes) and uses more sample volume (70 µl). 
Today, there is no doubt that the addition of 1-3-ßDG to a 
hospital where immunocompromised patients are cared is a neces-
sity, which is reinforced by the incorporation of the new test pres-
entations, easier to do and more functional. The determination of 
1-3-ßDG is already included in the most recent diagnostic guide-
lines for invasive mycoses [35, 36], although the frequency of the 
determinations is not clearly specified. Frequently, the rhythm has 
to do with the laboratory’s possibilities to perform the test, which is 
often done in batches, when enough samples have been accumu-
lated to make the test profitable. This causes clinicians to receive the 
test at an inadequate pace that does not anticipate clinical events 
and is inefficient. The availability of a test that allows daily perfor-
mance, without wasted materials and human resources, can change 
the clinical use of the test and its diagnostic and prognostic effec-
tiveness. 
Today, 1-3-βDG can be a powerful tool in an institution as 
long as it is properly used and interpreted.
Conclusion:
The presence of 1-3-β-D Glucan should be deter-
mined in patients with suspected invasive fungal disease, 
or as a follow-up to confirmed mycoses, provided that 
the timing of the determinations, data return, and test 
interpretation are properly applied.
QUESTION 6. What is the value of a positive or nega-
tive 1-3- β-D Glucan? What is the value of its evolution?
Dr. Miguel Salavert
Background:
A positive test for 1-3-ßDG, if the causes of false positives 
mentioned above are excluded, may suggest the presence of an IFI, 
not yet demonstrated by other methods, discriminates between col-
onization and infection in obviously colonized patients, reinforces 
the results of other diagnostic tests and contributes to the perfor-
mance of predictive scores.
In the meta-analysis of Karageorgopoulos et al. [37] the re-
sults of the 1-3-βDG of patients with or without criteria of cer-
tainty or probability of IFI, following the criteria of the EORTC, are 
compared in the analyzed studies, excluding cases of P. jirovecii 
infection. Of the 594 patients who met this condition, in the 16 
studies analyzed, the overall sensitivity of the test was 76.8% and 
its specificity 85.3%. AUCROC was 0.89 and it is concluded that 
1-3-BDG is a test with diagnostic precision to differentiate pa-
tients with IFI proven or probable from those who do not have it.
Lamoth´s et al. meta-analysis focuses on hematological pa-
Table 3  Some causes of false-positive results in 
the 1-3 ßDG test
•  Contamination of laboratory material with glucans.
•  Bacteremia due to Streptococcus spp. or some Gram-negative bacilli such as 
Pseudomonas spp.
•  Contact with surgical sponges and gauzes.
•  Hemodialysis patients with cellulose containing filters.
•  IV treatment with immunoglobulins, albumin or coagulation factors.
•  Antibacterial IV treatment with antibiotics such as amoxicillin-clavulanic or 
piperacillin-tazobactam.
•  Antineoplastic treatments with Lentinane or Polysaccharide k.
Table 4  Some causes of false-negative results in 
the 1-3-ßDG test
•  Hyperpigmented serums (bilirubin, triglycerides).
•  Antifungal treatment (prophylaxis, empirical).
•  Azithromycin or pentamidine IV.
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Martínez-Jiménez et al. used a combination of Can-
dida biomarkers in a group of 100 patients with bacte-
remia and candidemia including CAGTA, Mannan/Anti-
mannan (MN/AMN) and 1-3-ßDG (with different cut-off 
points) in patients undergoing antifungal treatment. Bi-
omarkers, used one by one, had limited sensitivity and 
specificity. Conversely, various combinations [45] such as 
the combination of CAGTA and 1-3-ßDG had, globally, a 
NPV of 97% for the diagnosis of IC. The best behavior of 
this combination of tests was observed in ICU patients.
Pini et al. [46] retrospectively studied the presence of 
CAGTA and 1-3-ßDG in stored serum samples from 29 patients 
with proven IC and 28 controls (9 with demonstrated bacter-
emia and 9 with negative blood cultures). The association of 
the two markers clearly increased the sensitivity and accuracy 
of the separate tests, with the two tests together achieving the 
following values: 97% sensitivity, 84% specificity, 78% PPV, 
95% NPV, and 84% accuracy.
Another possible combination that has been studied is 
the combination of 1-3-ßDG and procalcitonin (PCT) [47], 
in patients admitted to intensive care. The study evaluates 
the significance of 1-3-ßDG positive with PCT less than 2. 
The combination gives the following results: sensitivity of 
96%, specificity of 60%, PPV of 65% and NPV of 95%.
The combined use of 1-3-ßDG with GLM as ear-
ly markers of fungal infection was used in a monocen-
tric study that enrolled 270 suspected episodes of IFI, 58 
proven or probable IA, 27 proven IC, 11 possible IC, 16 P. 
jirovecii pneumonia (PJP) and 4 episodes of other IFI and 
154 non-IFI controls. The combination of 1-3-ßDG and 
GLM increased sensitivity from 60% to 83% in hematolog-
ical patients [48].
A recent meta-analysis included 13 studies evaluating 
combinations of GLM, 1-3-ßDG, and aspergillus-lateral flow 
device (A-LFD) for the diagnosis of IA [49]. Authors included 
1,513 patients. Pooled GLM and 1-3-ßDG combination data 
showed sensitivity of 49%, specificity of 98%, Positive Like-
lihood Ratio- PLR 32 (95%CI 5.36-187.37), NLR 0.52 (95%CI 
0.32-0.84) and DOR 61.23 (95%CI 6.96-538.90). The combina-
tions clearly increased their diagnostic value.
Conclusion:
The simultaneous combination of two or more bio-
markers improves both the sensitivity and the negative 
predictive value of the tests used separately and is there-
fore clinically useful.
QUESTION 8. Does the negativity of biomarker com-
binations allow early suspension of antifungal treatment?
Dr. Patricia Muñoz
Background:
Rouzé et al. [50] studied the impact of a strategy 
based on the use of biomarkers in the early discontinua-
tion of empirical antifungal treatments in ICU. A total of 
of disseminated fusariosis. In a group of 13 cases of fusa-
riosis, 12 had at least one positive test and in 11 of them 
the test was positive before diagnostic confirmation by 
other methods. Once treatment was started, the evolution 
of the determination was also interesting. The 1-3-ßDG 
continued to grow in patients who died within 30 days, 
while it was maintained or decreased in those who sur-
vived more than 1 month.
The determination of 1-3-βDG has also been carried 
out on material from bronchoalveolar lavages (BAL). In a 
meta-analysis that included data from 6 studies and 838 
patients (138 with proven or probable IFI), the accumulat-
ed sensitivity showed marginal efficacy data, that do not 
allow interpreting these results in isolation [42, 43].
Another aspect to discuss is the value of 1-3-ßDG fol-
low-up in patients already diagnosed with IFIs. The 1-3-
ßDG is a good biomarker of IFIs follow-up if the results 
are brought quickly to the clinician, which may allow the 
possibility of antifungal change or de-escalation of them. 
The control of the evolution of the fungal load can also 
influence the surgical or instrumental decision making and 
even in some mycoses allow epidemiological follow-up. In 
this field, however, methodologically correct studies are 
needed before clear conclusions can be drawn. Pini et al 
[44] have analyzed the prognostic potential of 1-3-ßDG in 
253 patients with IFIs who conclude with a positive (177 
episodes) or negative (76 episodes) evolution. Using an in-
terpretive algorithm based on two different breakpoints of 
significance, they were able to predict evolution in 82% 
of cases.
Conclusion:
Two consecutive positive blood tests for 1-3-ßDG, 
excluding the most frequent and obvious causes of false 
positivity, are associated with a high suspicion of invasive 
fungal infection. Its persistence or elevation in confirmed 
mycoses in antifungal treatment may be associated with 
poor prognosis.
QUESTION 7. What value does the simultaneous de-




Biomarkers do not provide categorical diagnoses, but 
are Bayesian parameters, which assign a probability of in-
fection (according to pre and post test probabilities). There 
are several reasons for using more than one biomarker. For 
example, when the suspected diagnosis is broad (Candida, 
filamentous fungi, etc.) and the possibilities of detection 
are to be expanded. With false negatives in mind, sever-
al biomarkers are used before suspending an empirically 
initiated antifungal treatment. On the contrary, and try-
ing to avoid the false positive effect, combinations of bio-
markers are used to avoid unnecessary treatments.
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ity >80 pg/mL) at some point (47 with candidemia and 
16 with probable IC) and all of them received antifungal 
treatment (31.8%). In the 135 negative 1-3-ßDG patients, 
110 (55.5%) never received antifungal treatment and 25 
(13%) received it only initially. Candidemia was only di-
agnosed in 1 patient who had not received previous anti-
fungal treatment. With this approach, the authors report-
ed that they were able to avoid unnecessary antifungal 
treatment in approximately 73% of potentially treatable 
patients and reduce duration in another 20% of cases.
The work of Rouzé et al.[50] who prospectively study the 
impact of a strategy of rapid suspension of empirically initiat-
ed antifungal treatments based on the results of 1-3-ßDG has 
also been commented on. This is a randomized study compar-
ing a group in which treatment is done according to stand-
ard recommendations and another that relies on biomarker 
results. As already commented, the biomarker-based strategy 
was basically safe and allowed a very substantial reduction in 
the unnecessary use of antifungals.
The data have therefore so far focused on the use of 
biomarkers to suspend theoretically unnecessary treat-
ments. In the case of patients with necessary treatments, 
we have not found data that would allow the evolution 
of biomarkers to be used as a strategy to shorten or ad-
just the duration of treatment either in candidemia with-
out organ candidiasis, or in candidemia with candidiasis 
of organs, or in the case of candidiasis of organs without 
accompanying candidemia. The dissociation between time 
to the negativity of blood cultures and time to the nega-
tivity of some biomarkers (T2Candida) allows speculation 
on their future use [55, 56].
Conclusion:
There are no data that permit to state, at this time, 
that biomarkers and their evolution can be used to adjust 
the duration of antifungal treatment in patients with in-
vasive fungal infection. 
QUESTION 10. To what extent are biomarkers going 




Invasive fungal infections (IFIs) increase their incidence in 
ICUs where approximately 80% are caused by Candida spp. and 
0.3-19% by Aspergillus spp.[57]. The problem of IC/candidemia 
in ICUs in Europe has been recently recalled with data from the 
EUCANDICU study which included 23 ICUs in 9 European coun-
tries. The cumulative incidence was 7 episodes per 1,000 admis-
sions with great variability between centers. Crude mortality at 
30 days was 42% [58]. We are, therefore, faced with a problem 
of enormous severity that requires intervention.
The problems related to IF Is in ICU patients are so com-
plex that they need to be addressed by collaborative groups, as 
suggested in the recommendations of the European Society of 
110 patients were randomized to an antifungal suspension 
strategy based on the combined use of 1-3-ßDG, mannan, 
and anti-mannan in serum on days 0 and + 4, compared 
to the usual standard, based on clinical practice guide-
lines and 14 days of treatment. In the biomarker-guided 
group, treatment was discontinued early in 29 of 54 pa-
tients compared with only 1 out of 55 early suspension in 
the group managed without biomarkers (54% vs 2%, p < 
0.001). The median duration of antifungal treatment was 
6 days versus 13 days, with no further differences in the 
occurrence of IC or differences in mortality between the 
two groups.
A cohort of 549 high-risk hematological patients un-
dergoing antifungal prophylaxis were followed with an-
tigenic determination and PCR [51]. The combination of 
techniques showed great utility in the management of IA, 
with high sensitivity (98%) and NPV (100%) when both 
tests were used together, allowing both early treatment 
and early suspension of antifungals. Biomarkers preceded 
clinical signs in 85% of cases of proven or probable IA.
The screening of IA is essential to decrease the em-
pirical use of antifungals. A meta-analysis of high-risk 
patients combining GLM and PCR weekly determination, 
included 13 studies and 1,670 patients [52]. The study 
concluded that the negativity of all the tests makes it pos-
sible to obviate the need to administer antifungal agents 
with an NPV of 100%, while the presence of at least 2 
positive tests is highly suggestive of active infection with 
a PPV of 88%.
Conclusion:
The negativity of two or more biomarkers of inva-
sive fungal infection supports the suspension of many 
empirical treatments and is an essential element of an 
adequate antifungal use policy, although prospective 
and well-designed studies are still needed to reinforce 
this concept.
QUESTION 9. Can biomarkers allow, in the future, the 
individualization of the duration of antifungal treatment?
Dr. José Garnacho-Montero
Background:
In a study carried out in Spain, and already commented [53], 
100 patients at high risk of IFI (63 in the ICU) were selected with 
empirical antifungal therapy. An IC could be tested in 30% of them. 
Determinations of CAGTA and 1-3-ßDG were made on days 0, 3 
and 5 after starting empirical antifungal therapy. The NPV of the 
combination of both tests was 97% and among non IC patients, all 
biomarkers were negative in 31/58 patients (53%) and there were 
27 false positive results. False positives were more common in the 
ICU (51.2%) than in general hospital wards (33.3%).
Posteraro et al. [54], in Massimo Antonelli’s group, de-
termined the effect of a 1-3-ßDG use strategy in patients 
at high risk of IC in an ICU. Out of a total of 198 patients, 
63 were 1-3-ßDG positive (cut-off value for BDG positiv-
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fect.2014;20(4):O245-54. DOI 10.1111/1469-0691.12380.
3. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, 
Almela M, et al. Epidemiology and predictors of mortality in cases 
of Candida bloodstream infection: results from population-based 
surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 
2005;43(4):1829-35. DOI 10.1128/jcm.43.4.1829-1835.2005.
4. Rodriguez-Hernandez MJ, Ruiz-Perez de Pipaon M, Marquez-Sole-
ro M, Martin-Rico P, Caston-Osorio JJ, Guerrero-Sanchez FM, et 
al. Candidemias: multicentre analysis in 16 hospitals in Andalu-
sia (Spain). Enferm Infecc Microbiol Clin. 2011;29(5):328-33. DOI 
10.1016/j.eimc.2010.12.003.
5. Cisterna R, Ezpeleta G, Telleria O. Nationwide sentinel surveil-
lance of bloodstream Candida infections in 40 tertiary care hos-
pitals in Spain. J Clin Microbiol. 2010;48(11):4200-6. DOI 10.1128/
jcm.00920-10.
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Epidemiology, species distribution and in vitro antifungal suscep-
tibility of fungaemia in a Spanish multicentre prospective survey. 
J Antimicrob Chemother. 2012;67(5):1181-7. DOI 10.1093/jac/
dks019.
7. Calandra T, Roberts JA, Antonelli M, Bassetti M, Vincent JL. Di-
agnosis and management of invasive candidiasis in the ICU: an 
updated approach to an old enemy. Crit Care (London, England). 
2016;20(1):125. DOI 10.1186/s13054-016-1313-6.
8. Pitarch A, Nombela C, Gil C. Diagnosis of Invasive Candidiasis: From 
Gold Standard Methods to Promising Leading-edge Technologies. 
Curr Top Med Chem. 2018;18(16):1375-92. DOI 10.2174/15680266
18666181025093146.
9. Lass-Florl C. How to make a fast diagnosis in invasive aspergillo-
sis. Med Mycol 2019;57(Supplement_2):S155-s60. 10.1093/mmy/
myy103.
10. Schauwvlieghe A, de Jonge N, van Dijk K, Verweij PE, Bruggemann 
RJ, Biemond BJ, et al. The diagnosis and treatment of invasive as-
pergillosis in Dutch haematology units facing a rapidly increasing 
prevalence of azole-resistance. A nationwide survey and rationale 
for the DB-MSG 002 study protocol. Mycoses. 2018;61(9):656-64. 
DOI 10.1111/myc.12788.
11. Cuenca-Estrella M. Laboratory diagnosis of fungal infection diseas-
es. Enferm Infecc Microbiol Clin. 2012;30(5):257-64. DOI 10.1016/j.
eimc.2012.01.019.
12. Clancy CJ, Nguyen MH. Diagnosing Invasive Candidiasis. J Clin Mi-
crobiol. 2018;56(5). DOI 10.1128/jcm.01909-17.
13. Patterson TF, Donnelly JP. New Concepts in Diagnostics for Invasive 
Mycoses: Non-Culture-Based Methodologies. J Fungi (Basel, Swit-
zerland). 2019;5(1). DOI 10.3390/jof5010009.
14. Ayats J, Martin-Mazuelos E, Peman J, Quindos G, Sanchez F, Gar-
cia-Rodriguez J, et al. Spanish Society of Clinical Microbiology and 
Infectious Diseases (SEIMC) guidelines for the diagnosis of inva-
sive fungal infections. 2010 update. Enferm Infecc Microbiol Clin. 
2011;29(1):39.e1-15. DOI 10.1016/j.eimc.2010.08.005
15. Wei S, Wu T, Wu Y, Ming D, Zhu X. Diagnostic accuracy of Can-
dida albicans germ tube antibody for invasive candidiasis: sys-
Intensive Care Medicine (ESICM) and the Critically Ill Patients 
Study Group of the European Society of Clinical Microbiology 
and Infectious Diseases (ESCMID) [59] and should result in the 
establishment of a stewardship for the rational use of antifun-
gals specifically focused on ICU patients.
Biomarkers are, and will be, an essential element of a pol-
icy of diagnostic anticipation and rational use of antifungals. 
The combined use of CAGTA and 1-3-ßDG in two consecutive 
samples of ICU patients in Spain, showed 90 % sensitivity, 42 
% specificity and 97 % NPV, also allowing a reasonable dis-
criminatory use between colonization and invasion in patients 
with severe intra-abdominal diseases [17].
Candida biomarkers such as CAGTA, 1-3-ßDG and others 
need even more research and studies to demonstrate the clinical 
impact of their systematic use. Future studies should specifically 
address the use of different diagnostic and therapeutic strate-
gies in patients with intra-abdominal candidiasis [57].
Finally, it is clear that the availability of biomarkers will 
not delay empirical treatment and therefore will probably 
reduce mortality. Biomarkers will permit suspension of treat-
ments if negative, in the relevant clinical context, and avoid 
the overuse of antifungals with considerable ecological and 
economic benefits.
Conclusion:
Candida biomarkers introduce a new era in Intensive 
Care Units. They will allow a diagnostic and therapeutic 
anticipation with the consequent decrease in mortality, 
an early discontinuation of unnecessary empirical treat-
ments. Biomarkers will represent an excellent contribu-
tion to antifungal stewardship
FINAL REMARK
At the time of finishing the edition of this manuscript, 
during the month of October 2019, a Guideline of the Ameri-
can Thoracic Society has appeared, referring to the microbio-
logical diagnosis of pulmonary fungal infections that we con-
sider of particular relevance and we recommend to read to the 
readers of this text [60].
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